Certara (NASDAQ:CERT – Get Free Report) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.310-0.340 for the period, compared to the consensus estimate of 0.310. The company issued revenue guidance of $427.2 million-$431.4 million, compared to the consensus revenue estimate of $380.9 million.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on CERT shares. Barclays upped their price objective on Certara from $9.00 to $12.00 and gave the stock an “equal weight” rating in a research note on Friday. Weiss Ratings downgraded shares of Certara from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, October 8th. TD Cowen boosted their price objective on shares of Certara from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. KeyCorp lifted their price target on Certara from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. Finally, UBS Group reaffirmed a “neutral” rating and set a $13.00 price target on shares of Certara in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Certara currently has a consensus rating of “Hold” and an average target price of $9.92.
View Our Latest Stock Report on CERT
Certara Trading Down 1.1%
NASDAQ:CERT opened at $12.05 on Friday. The firm has a market cap of $1.84 billion, a P/E ratio of -28.69 and a beta of 1.30. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.55 and a current ratio of 2.55. The firm’s fifty day moving average is $9.33 and its 200-day moving average is $7.35. Certara has a 52 week low of $4.45 and a 52 week high of $12.61.
Certara (NASDAQ:CERT – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.09. The firm had revenue of $94.90 million for the quarter, compared to the consensus estimate of $92.01 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%. The company’s revenue for the quarter was down 9.3% on a year-over-year basis. During the same period last year, the business posted $0.14 EPS. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. Equities analysts expect that Certara will post 0.21 earnings per share for the current year.
Certara News Roundup
Here are the key news stories impacting Certara this week:
- Positive Sentiment: Certara raised its 2026 revenue outlook to $427.2 million–$431.4 million, well above the cited analyst consensus of $380.9 million. Its EPS guidance of $0.31–$0.34 also met or exceeded the $0.31 consensus midpoint, giving investors a stronger forward outlook. Article: Certara Q3 2026 Earnings Call Highlights
- Positive Sentiment: Third-quarter revenue of $94.9 million topped the $92.0 million consensus, while EPS was reported at $0.09, meeting some estimates and exceeding others. Reports also highlighted double-digit software revenue growth—the first such pace in two years—which helped support a positive share-price reaction after the update. Article: Certara Q3 2026 earnings
- Neutral Sentiment: Barclays raised its price target from $9 to $12 but kept an Equal Weight rating, signaling improved valuation expectations without a bullish call. Article: Barclays price target update
- Negative Sentiment: UBS downgraded CERT from Buy to Neutral, though its $13 price target remains above the price cited in the report. The downgrade may restrain enthusiasm after the stock’s recent rally. Article: UBS downgrades Certara
About Certara
Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.
Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.
Recommended Stories
- Five stocks we like better than Certara
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
